Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib

Kai Sun, Saro Kasparian, Swaminathan Iyer, Sai Ravi Pingali

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Ibrutinib, a Bruton's tyrosine kinase inhibitor, has been increasingly widely used in relapsed and refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia [1, 2]. With its use becoming more common, there have been emerging case reports of opportunistic infections like cryptococcal infections [3-8]. These infections in patients receiving ibrutinib were mostly reported in patients with chronic lymphocytic leukaemia, who have poor immune reconstitution. Here, we report two cases of cryptococcal meningoencephalitis in patients with MCL on ibrutinib.

Original languageEnglish (US)
Article number836
StatePublished - May 17 2018


  • Cryptococcal meningoencephalitis
  • Ibrutinib
  • Mental cell lymphoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib'. Together they form a unique fingerprint.

Cite this